The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons
Open accessAbstract
Angelman syndrome is a severe neurodevelopmental disorder caused by deletion or mutation of the maternal allele of the ubiquitin protein ligase E3A (UBE3A). In neurons, the paternal allele of UBE3A is intact but epigenetically silenced, raising the possibility that Angelman syndrome could be treated by activating this silenced allele to restore functional UBE3A protein. Using an unbiased, high-content screen in primary cortical neurons from mice, we identify twelve topoisomerase I inhibitors and four topoisomerase II inhibitors that unsilence the paternal Ube3a allele. These drugs included topotecan, irinotecan, etoposide and dexrazoxane (ICRF-187). At nanomolar concentrations, topotecan upregulated catalytically active UBE3A in neurons from maternal Ube3a-null mice. Topotecan concomitantly downregulated expression of the Ube3a antisense transcript that overlaps the paternal copy of Ube3a. These results indicate that topotecan unsilences Ube3a in cis by reducing transcription of an imprinted antisense RNA. When administered in vivo, topotecan unsilenced the paternal Ube3a allele in several regions of the nervous system, including neurons in the hippocampus, neocortex, striatum, cerebellum and spinal cord. Paternal expression of Ube3a remained elevated in a subset of spinal cord neurons for at least 12 weeks after cessation of topotecan treatment, indicating that transient topoisomerase inhibition can have enduring effects on gene expression. Although potential off-target effects remain to be investigated, our findings suggest a therapeutic strategy for reactivating the functional but dormant allele of Ube3a in patients with Angelman syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, paternal-specific deletion of multiple imprinted, paternally expressed genes on the 15q11–q13 region results in Prader–Willi syndrome, whereas maternal deletion of a single, imprinted, maternally expressed gene encoding a ubiquitin-protein ligase (UBE3A) on this same region gives rise to the Angelman syndrome phenotype.”
From Gene × Environment Interactions in Autism Spectrum Disorders: Role of Epigenetic Mechanisms (2014) · cites this paper as [193]
In the citing paper
“Using an unbiased screen in primary cortical neurons from mice, Huang et al. 101 identified several topoisomerase inhibitors that unsilence the paternal allele of UBE3A”
From Progress toward treatments for synaptic defects in autism (2013) · cites this paper as [101]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abràmoff, M. D., Magalhães, P. J., & Ram, S. J. (2004) · Utrecht University Repository (Utrecht University) · Cited by 11,816
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. G. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1977 · Cited by 2,362
Stability and flexibility of epigenetic gene regulation in mammalian development
Reik, W. (2007) · Nature · doi:10.1038/nature05918 · Cited by 1,963 · cited 1×
“Genomic imprinting is thought to be established only during prescribed germline and embryonic periods of development and imprinted genes typically remain epigenetically regulated throughout lif”
BackgroundUBE3A/E6-AP mutations cause Angelman syndrome
Kishino, T., Lalande, M., & Wagstaff, J. E. (1997) · Nature Genetics · doi:10.1038/ng0197-70 · Cited by 1,304
Protein ubiquitination involving an E1–E2–E3 enzyme ubiquitin thioester cascade
Scheffner, M., Nuber, U. A., & Huibregtse, J. M. (1995) · Nature · doi:10.1038/373081a0 · Cited by 1,017
CellProfiler™: Free, Versatile Software for Automated Biological Image Analysis
Lamprecht, M. R., Sabatini, D. M., & Carpenter, A. E. (2007) · BioTechniques · doi:10.2144/000112257 · Cited by 880
De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome
Matsuura, T., Sutcliffe, J. S., Fang, P., Galjaard, R. H., Jiang, Y., Benton, C. S., Rommens, J. M., & Beaudet, A. L. (1997) · Nature Genetics · doi:10.1038/ng0197-74 · Cited by 858
Jiang, Y.-H., Armstrong, D., Albrecht, U., Atkins, C. M., Noebels, J. L., Eichele, G., Sweatt, J. D., & Beaudet, A. L. (1998) · Neuron · doi:10.1016/s0896-6273(00)80596-6 · Cited by 852
Albrecht, U., Sutcliffe, J. S., Cattanach, B. M., BEECHEY, C. V., Armstrong, D. L., Gregor Eichele, C., & Beaudet, A. L. (1997) · Nature Genetics · doi:10.1038/ng0997-75 · Cited by 587
Nakatani, J., Tamada, K., Hatanaka, F., Ise, S., Ohta, H., Inoue, K., Tomonaga, S., Watanabe, Y., Chung, Y. J., Banerjee, R., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.024 · Cited by 482
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–391 of 391
Giannini, G. (2014) · Methods and principles in medicinal chemistry · doi:10.1002/9783527676545.ch05 · Cited by 3
Çelen, İ., Doh, J. H., & Sabanayagam, C. R. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/194506 · Cited by 3
Atypical alpha oscillatory EEG dynamics in children with Angelman syndrome
Dickinson, A. H., Bowen-Kauth, M. S., Shide, J. J., Youngkin, A. E., Hosamane, N. S., McNair, C. A., Ryan, D. P., Chu, C. J., & Sidorov, M. S. (2025) · NeuroImage Clinical · doi:10.1016/j.nicl.2025.103865 · Cited by 2
RNAi-Induced Expression of Paternal UBE3A
Kang, H. R., Zaric, V., Rybalchenko, V., Gray, S. J., & Butler, R. K. (2026) · Genes · doi:10.3390/genes17020156 · Cited by 2
A dual-reporter mouse for therapeutic discovery in Angelman syndrome
Vihma, H., James, L., Nourie, H. C., Smith, A. L., Liang, S., Friar, C. A., Vulli, T., Xing, L., Cowley, D. O., Burette, A. C., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.197028 · Cited by 2
Self-citationTaylor, A. J., Foley, N. M., Childers, I. R., Murphy, W. J., & Dindot, S. V. (2026) · Journal of Heredity · doi:10.1093/jhered/esag019 · Cited by 2
Variations on a Theme: Crispr Models for 15q11-Q13 Disorders and Beyond
Bailus, B. J. (2014) · Brain Disorders & Therapy · doi:10.4172/2168-975x.1000146 · Cited by 2
Синдром Ангельмана. Часть 3 (дифференциальная диагностика и лечение)
Абатуров, А. Е., Petrenko, L. L., & Kryvusha, O. L. (2020) · CHILD`S HEALTH · doi:10.22141/2224-0551.7.67.2015.75100 · Cited by 2
Progress in The Molecular Genetic Research in Autism Spectrum Disorders
Han, X., Peng, R., Zhang, L., & Shi, Z. (2019) · Journal of Psychiatry and Psychiatric Disorders · doi:10.26502/jppd.2572-519x0068 · Cited by 2
Imprinting analysis by droplet digital PCR coupled with locked nucleic acid TaqMan probes
Mitake, M., Hirano, S., & Kishino, T. (2020) · Epigenetics · doi:10.1080/15592294.2020.1823160 · Cited by 2
Developmental disabilities, autism, and schizophrenia at a single locus
Reiter, L. T. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-814409-1.00009-4 · Cited by 2
Drebushenko, L., Belous, N., Lischka, F. W., Zhou, Q., Malci, A., Sidorov, M. S., Burnett, B. G., & Doughty, M. L. (2025) · Molecular and Cellular Biology · doi:10.1080/10985549.2025.2470431 · Cited by 2
Unsilencing dormant Ube3a—hope for Angelman syndrome?
Malpass, K. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.2 · Cited by 2
Prader–Willi and Angelman syndromes
Smith, E. Y., & Resnick, J. L. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107360556.019 · Cited by 2
Recent Advances in Imprinting Disorders
Hussain, N. (2017) · NeoReviews · doi:10.1542/neo.18-9-e532 · Cited by 2
Mendelian, non-Mendelian, multigenic inheritance, and epigenetics
Harel, T., & Lupski, J. R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813955-4.00001-5 · Cited by 2
Crabtree, G. R., Son, E., Krokhotin, A., Gourisankar, S. P., & Chang, C.-Y. (2021) · Research Square · doi:10.21203/rs.3.rs-959800/v1 · Cited by 2
Courtship and distress ultrasonic vocalizations are altered in a mouse model of Angelman syndrome
Guoynes, C. D., Pavalko, G., & Sidorov, M. S. (2025) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-025-09648-y · Cited by 1
Miller, A. H., Yang, Y., Schmidt, N., Mathiaparanam, J., Berres, M. E., & Halloran, M. C. (2026) · Disease Models & Mechanisms · doi:10.1242/dmm.052509 · Cited by 1
UBE3A isoform-selective and non-selective contributions to Angelman syndrome phenotypes
Krzeski, J. C., Mientjes, E., Judson, M. C., Dong, G., Hipp, R. I., Lien, K. H., Gu, B., Philpot, B. D., & Elgersma, Y. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03468-9 · Cited by 1
Self-citationE3 ubiquitin ligases in neurodegenerative diseases
Hou, D. L., Ho, J., Guan, T., Dong, X.-X., Zeng, L., Sanders, L. H., Wu, Y., Tan, E., & Zhou, Z. D. (2026) · Military Medical Research · doi:10.1016/j.mmr.2026.100032 · Cited by 1
Bazick, H., James, L. M., & Zylka, M. J. (2026) · Scientific Reports · doi:10.1038/s41598-026-52498-4 · Cited by 1
Self-citationEmerging Therapies for Angelman Syndrome
Tychon, C., Markati, T., Alkan, S., Brande, L. V., & Servais, L. (2026) · CNS Drugs · doi:10.1007/s40263-026-01313-9 · Cited by 1
Kurmashev, R. (2026) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.70025 · Cited by 1
Cellular and Animal Models of Neurologic Disease
Rangasamy, S., Narayanan, M. J., Schrauwen, I., Muotri, A. R., & Narayanan, V. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-37101-8.00016-3 · Cited by 1
Williams, C. A., & Mueller, J. M. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-410529-4.00020-6 · Cited by 1
Prenatal Exposure to Azadiradione Leads to Developmental Disabilities
Jana, S., Das, S., Giri, B., Archak, R., Bandyopadhyay, S., & Jana, N. R. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04493-x · Cited by 1
Long Noncoding RNA in Epigenetic Gene Regulation
Hasegawa, Y., & Nakagawa, S. (2015) · Springer eBooks · doi:10.1007/978-4-431-55576-6_8 · Cited by 1
Therapeutic Approaches to Imprinting Diseases
Hattori, H., Hiura, H., Kobayashi, N., Takahashi, S., Okae, H., & Arima, T. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812215-0.00028-5 · Cited by 1
Induced pluripotent stem cells for modeling Angelman syndrome
Maranga, C., Vieira, A. A., Bekman, E., & da Rocha, S. T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85764-2.00015-6 · Cited by 1
Novel strategies to cure imprinting disorders
Horsthemke, B., & Zechner, U. (2020) · Medizinische Genetik · doi:10.1515/medgen-2020-2043 · Cited by 1
Graw, J. (2020) · Springer eBooks · doi:10.1007/978-3-662-60909-5_8 · Cited by 1
De, S. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-13312-1.00010-6 · Cited by 1
Epigenetic Regulation in Autism
Peter, C. J., Reichenberg, A., & Akbarian, S. (2015) · Contemporary clinical neuroscience · doi:10.1007/978-1-4939-2190-4_5 · Cited by 1
Epigenetics in Brain Development and Disease
Radford, E. J., Ferguson‐Smith, A. C., & Ferrón, S. R. (2017) · Wiley eBooks · doi:10.1002/9781118540770.ch14 · Cited by 1
Brain-wide Genome Editing via STEP-RNPs for Treatment of Angelman SyndromePreprint
Lu, X., Xie, Y., Bao, Y., Yu, J., Wang, Z., Fan, J., Sheu, W. C., Long, G., Tu, Z., Tong, J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.13.684643 · Cited by 1
He, B., Mao, Y., Hong, C., & Geng, Y. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.24.707855 · Cited by 1
Recurrent CNVs in the Etiology of Epigenetic Neurodevelopmental Disorders
LaSalle, J. M., & Islam, M. S. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8078-5_7
The Mind and its Nucleosomes – Chromatin (dys)Regulation in Major Psychiatric Disease
Bharadwaj, R. A., Peter, C. J., & Akbarian, S. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-391494-1.00007-0
Filonova, I. (2014) · Digital Commons - University of South Florida (University of South Florida)
Genetic studies of neurodevelopmental disorders
Wincent, J. (2012) · Figshare
Grieco, J. C. (2015) · Digital Commons - University of South Florida (University of South Florida)
A wake-up call for dormant genes
Hill, R. L. (2011) · Nature · doi:10.1038/nature.2011.9700
Harnessing Induced Pluripotent Stem Cells For the Modeling and Treatment of Neurological Disorders
Bar‐Nur, O. (2012) · Future Neurology · doi:10.2217/fnl.12.57
Childhood Disorders of the Synapse: Challenges and Opportunities
HUGHES, V. A., Sheng, M., & Zoghbi, H. Y. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004356
Therapiekonzepte bei genetischen Syndromen mit mentaler Retardierung
Omran, H., Kunde-Trommer, J., & Blank, R. (2014) · Elsevier eBooks · doi:10.1016/b978-3-437-23076-9.00003-6
Topotécan, espoir thérapeutique dans le syndrome d’Angelman ?
Dan, B., Pelc, K., & Cheron, G. A. (2012) · médecine/sciences · doi:10.1051/medsci/2012286005
Social dysfunction and mental retardation
Pietropaolo, S., Sluyter, F., & Crusio, W. E. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107360556.010
Characterization of Salicylates as Novel Catalytic Inhibitors of Human DNA Topoisomerase II Alpha
Bau, J. T. (2014) · Libraries and Cultural Resources (University of Calgary) · doi:10.11575/prism/25289
Developing novel therapeutic strategies for Rett syndrome
Ross, P. D. (2016) · Enlighten: Theses (The University of Glasgow)
Neuropädiatrische Differenzialdiagnostik der Mikrozephalie im Kindesalter
von der Hagen, M., Hennermann, J. B., von Bernuth, H., John, R., Spors, B., & Kaindl, A. M. (2016) · Medizinische Genetik · doi:10.1007/s11825-016-0081-7
Imprinting in the CNS and Neurodevelopmental Disorders
Powell, W. T., & LaSalle, J. M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-391494-1.00010-0
Rigoglio, N. N. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.10.2016.tde-30052016-154726
Cruvinel, E. M. (2015) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.41.2015.tde-24092015-133351
The Angelman Approach : hacking DNA to treat a rare disease
Levy, B. A. (2017)
Using a chemical genetics approach to dissect the nitrogen signalling pathway in Arabidopsis
Gent, L. (2018) · Rothamsted Repository (Rothamsted Repository) · doi:10.17635/lancaster/thesis/268
White, K. L. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/q73z-g116
Townsend, L. (2017) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/1g4n-6f83
Tools for the Advancement of Cell-based Screening for Neurological Disorders
Gordon, K. R. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/5qhe-m809
Brain‐specific monoallelic expression of bovine UBE3A is associated with genomic position
Li, J., Zhang, C., Si, H., Gu, S., Liu, X., Li, D., Meng, S., Yang, X., & Li, S. (2020) · Animal Genetics · doi:10.1111/age.13023
The Road to Personalized Therapies: Lessons Learned From Angelman Syndrome
Duis, J. B. (2022) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-127.2.95
Personalized Epigenetics: Prospects and Challenges
Caianiello, S. (2022) · Human perspectives in health sciences and technology · doi:10.1007/978-3-030-74804-3_12
Graw, J. (2015) · Springer eBooks · doi:10.1007/978-3-662-44817-5_8
Faculty Opinions recommendation of The Top1 paradox: Friend and foe of the eukaryotic genome.
Kaufmann, S. H. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727745036.793565196
Novel Approaches for Treating Pediatric Psychiatric Disorders
Prasad, S., & Cook, E. H. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780190681425.003.0067
CRISPR technology and its potential role in treating rare imprinting diseases
Nickl, P., Syding, L. A., & Sedláček, R. (2023) · Principles of Gender-Specific Medicine · doi:10.1016/b978-0-323-88534-8.00044-4
Therapeutic approaches to imprinting diseases
Sassi, H., Guerrini‐Rousseau, L., Grill, J., & Rouleau, É. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-21863-7.00013-5
Targeted Augmentation of Nuclear Gene Output (TANGO)
Isom, L. L., & Knupp, K. G. (2024) · Oxford University Press eBooks · doi:10.1093/med/9780197549469.003.0075
Nambiar, A. G., Biswas, A. A., Agrawal, A. K., Mishra, B., & Kumar, D. (2024) · Springer eBooks · doi:10.1007/978-981-97-5016-0_8
Mendelian, non-Mendelian, multigenic inheritance, and epigenetics
Harel, T., & Lupski, J. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19041-4.00019-4
Epigenetic Therapies in Neurological Diseases
Huang, H., Philpot, B. D., & Jiang, Y. (2013) · Epigenetics and human health · doi:10.1007/978-3-642-36827-1_8
Self-citationLee, H.-M., Kuijer, M. B., Blanes, N. R., Clark, E. P., Aita, M., Galiano Arjona, L., Kokot, A., Sciaky, N., Simon, J. M., Bhatnagar, S., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13219493
Self-citationLee, H.-M., Kuijer, M. B., Blanes, N. R., Clark, E. P., Aita, M., Galiano Arjona, L., Kokot, A., Sciaky, N., Simon, J. M., Bhatnagar, S., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13219490
Self-citationLee, H.-M., Kuijer, M. B., Blanes, N. R., Clark, E. P., Aita, M., Galiano Arjona, L., Kokot, A., Sciaky, N., Simon, J. M., Bhatnagar, S., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13219496
Self-citationEhrenhofer‐Murray, A. E. (2025) · Springer eBooks · doi:10.1007/978-3-662-70328-1_8
Penna, E., Pizzella, A., Abate, N., Conte, N., Cimmino, F., Mollica, M. P., Giaimo, R. D., Baudry, M., Bi, X., & Crispino, M. (2026) · Experimental Neurology · doi:10.1016/j.expneurol.2026.115689
Identification et caractérisation de la fonction d’un réseau de gènes soumis à empreinte
Evano, B. (2012) · theses.fr (ABES) · doi:10.70675/145f92d8zdf33z4b39za037z390f530f7be0
Cristini, A. (2015) · theses.fr (ABES) · doi:10.70675/89719cadza51cz4509zbd9fz3da99c280491
Generation of antisense RNAs at convergent gene loci in cells undergoing senescence
Deb, M. K. (2016) · theses.fr (ABES) · doi:10.70675/739ebf07zf620z4e1fzb0d4z02066589491f
Welton-Arndt, A., Nourie, H. C., Vihma, H., Liang, S., Super, J., Li, K., Collins, J. L., Huang, H.-C., Zhang, A., Trojniak, A. E., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00168
Self-citationCurrent hypothesis for AD progression
Kim, C. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45844-6.00016-0
Operant behavior is reliably impaired in a mouse model of Angelman syndrome
Guoynes, C. D., Kerr, D. D., Hotait, Z. S., Tanas, J. K., & Sidorov, M. S. (2026) · Scientific Reports · doi:10.1038/s41598-026-71483-5
E3 Ubiquitin Ligases in Neurodevelopmental Disorders
Wang, S., Pan, X., Zhang, K., Zhao, D., Chen, X., Wang, Y., Hu, H., & Zhang, Y. (2026) · Cells · doi:10.3390/cells15181703
Self-citationBindingDB Entry 50049186: Type I DNA Topoisomerases.
BindingDB (2019) · UC San Diego · doi:10.7270/q2cr5wmb
Metadata
- Authors
- Huang, H.-S., Allen, J. A., Mabb, A. M., King, I. F., Miriyala, J., Taylor-Blake, B., Sciaky, N., Dutton, J. W., Lee, H.-M., Chen, X., Jin, J., Bridges, A. S., Zylka, M. J., Roth, B. L., & Philpot, B. D.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Zylka, Mark J.
- Roth, Bryan L.
- Philpot, Benjamin D.
- ORCID
- Venue
- Nature
- Published
- 2011-12-21
- Volume
- 481
- Issue
- 7380
- Pages
- 185-189
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3257422
- OpenAlex
- W2016365513
- Cited by
- 387
- References
- 38
- Citations by year
- 2026: 15 · 2025: 19 · 2024: 18 · 2023: 18 · 2022: 17 · 2021: 15 · 2020: 34 · 2019: 24 · 2018: 22 · 2017: 33 · 2016: 37 · 2015: 34 · 2014: 38 · 2013: 35 · 2012: 26
- FWCI
- 20.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- U.S. Public Health Service (HHSN-271-2008-00025-C)
- National Institute of Mental Health (R01MH093372)
- National Eye Institute (R01EY018323)
- National Institute of Neurological Disorders and Stroke (R01NS060725, R01NS067688, P30NS045892, F32NS067712)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (P30-HD03110, P30HD003110, T32HD040127)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Syndromes and Imprinting
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- Angelman syndrome, UBE3A, genomic imprinting, topoisomerase inhibitors, topotecan, epigenetic silencing, antisense RNA, cortical neurons, irinotecan, etoposide, dexrazoxane, drug repurposing, long-term drug effects
- MeSH terms
- Alleles, Animals, Cells, Cultured, Cerebral Cortex, Drug Evaluation, Preclinical, Fathers, Female, Male, Mice, Inbred C57BL, Mothers, Neurons, Angelman Syndrome, Genomic Imprinting, Topotecan, Gene Silencing, Ubiquitin-Protein Ligases, Mice, Small Molecule Libraries, Topoisomerase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
